S&P 500   3,369.31 (-0.33%)
DOW   27,847.77 (-0.46%)
QQQ   272.22 (+0.13%)
AAPL   458.43 (+1.41%)
MSFT   208.77 (-0.20%)
FB   260.05 (+0.06%)
GOOGL   1,514.56 (+0.49%)
AMZN   3,171.50 (+0.29%)
NVDA   457.40 (-0.05%)
CGC   17.29 (+0.23%)
BABA   253.53 (-0.65%)
TSLA   1,603.52 (+3.14%)
GE   6.62 (-1.49%)
MU   46.12 (-4.87%)
AMD   81.91 (-0.85%)
T   29.89 (-0.96%)
F   7.02 (-1.27%)
ACB   10.27 (+4.80%)
GILD   68.20 (-0.93%)
NFLX   481.56 (+1.28%)
DIS   130.74 (-0.80%)
BAC   26.21 (-1.95%)
BA   174.53 (-0.52%)
S&P 500   3,369.31 (-0.33%)
DOW   27,847.77 (-0.46%)
QQQ   272.22 (+0.13%)
AAPL   458.43 (+1.41%)
MSFT   208.77 (-0.20%)
FB   260.05 (+0.06%)
GOOGL   1,514.56 (+0.49%)
AMZN   3,171.50 (+0.29%)
NVDA   457.40 (-0.05%)
CGC   17.29 (+0.23%)
BABA   253.53 (-0.65%)
TSLA   1,603.52 (+3.14%)
GE   6.62 (-1.49%)
MU   46.12 (-4.87%)
AMD   81.91 (-0.85%)
T   29.89 (-0.96%)
F   7.02 (-1.27%)
ACB   10.27 (+4.80%)
GILD   68.20 (-0.93%)
NFLX   481.56 (+1.28%)
DIS   130.74 (-0.80%)
BAC   26.21 (-1.95%)
BA   174.53 (-0.52%)
S&P 500   3,369.31 (-0.33%)
DOW   27,847.77 (-0.46%)
QQQ   272.22 (+0.13%)
AAPL   458.43 (+1.41%)
MSFT   208.77 (-0.20%)
FB   260.05 (+0.06%)
GOOGL   1,514.56 (+0.49%)
AMZN   3,171.50 (+0.29%)
NVDA   457.40 (-0.05%)
CGC   17.29 (+0.23%)
BABA   253.53 (-0.65%)
TSLA   1,603.52 (+3.14%)
GE   6.62 (-1.49%)
MU   46.12 (-4.87%)
AMD   81.91 (-0.85%)
T   29.89 (-0.96%)
F   7.02 (-1.27%)
ACB   10.27 (+4.80%)
GILD   68.20 (-0.93%)
NFLX   481.56 (+1.28%)
DIS   130.74 (-0.80%)
BAC   26.21 (-1.95%)
BA   174.53 (-0.52%)
S&P 500   3,369.31 (-0.33%)
DOW   27,847.77 (-0.46%)
QQQ   272.22 (+0.13%)
AAPL   458.43 (+1.41%)
MSFT   208.77 (-0.20%)
FB   260.05 (+0.06%)
GOOGL   1,514.56 (+0.49%)
AMZN   3,171.50 (+0.29%)
NVDA   457.40 (-0.05%)
CGC   17.29 (+0.23%)
BABA   253.53 (-0.65%)
TSLA   1,603.52 (+3.14%)
GE   6.62 (-1.49%)
MU   46.12 (-4.87%)
AMD   81.91 (-0.85%)
T   29.89 (-0.96%)
F   7.02 (-1.27%)
ACB   10.27 (+4.80%)
GILD   68.20 (-0.93%)
NFLX   481.56 (+1.28%)
DIS   130.74 (-0.80%)
BAC   26.21 (-1.95%)
BA   174.53 (-0.52%)
Log in

NASDAQ:TGTXTG Therapeutics Stock Price, Forecast & News

$19.94
+0.89 (+4.67 %)
(As of 08/13/2020 03:18 PM ET)
Add
Compare
Today's Range
$18.90
Now: $19.94
$20.33
50-Day Range
$18.22
MA: $20.93
$24.15
52-Week Range
$4.95
Now: $19.94
$24.76
Volume56,079 shs
Average Volume2.09 million shs
Market Capitalization$2.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.41
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton's Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Read More
TG Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Price / Sales14,645.00
Book Value$0.39 per share

Profitability

Net Income$-172,870,000.00
Net Margins-124,230.27%

Miscellaneous

Employees105
Market Cap$2.20 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$19.94
+0.89 (+4.67 %)
(As of 08/13/2020 03:18 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

How has TG Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TGTX stock has increased by 99.2% and is now trading at $19.94.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TG Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TG Therapeutics
.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for TG Therapeutics
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics Inc (NASDAQ:TGTX) issued its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.15. TG Therapeutics had a negative net margin of 124,230.27% and a negative return on equity of 2,937.74%.
View TG Therapeutics' earnings history
.

What price target have analysts set for TGTX?

4 brokers have issued 1 year price targets for TG Therapeutics' stock. Their forecasts range from $35.00 to $60.00. On average, they expect TG Therapeutics' share price to reach $42.50 in the next year. This suggests a possible upside of 113.1% from the stock's current price.
View analysts' price targets for TG Therapeutics
.

Has TG Therapeutics been receiving favorable news coverage?

News coverage about TGTX stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TG Therapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about TG Therapeutics
.

Who are some of TG Therapeutics' key competitors?

What other stocks do shareholders of TG Therapeutics own?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 53)
  • Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 37)
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.40%), Goldman Sachs Group Inc. (1.02%), Barclays PLC (0.84%), Bank of New York Mellon Corp (0.40%), Raymond James & Associates (0.22%) and California Public Employees Retirement System (0.20%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Sean A Power and William James Kennedy.
View institutional ownership trends for TG Therapeutics
.

Which major investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including AlphaCrest Capital Management LLC, UBS Group AG, Raymond James & Associates, Virtus ETF Advisers LLC, Goldman Sachs Group Inc., Raymond James Financial Services Advisors Inc., Exane Derivatives, and Arizona State Retirement System.
View insider buying and selling activity for TG Therapeutics
.

Which major investors are buying TG Therapeutics stock?

TGTX stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., EAM Investors LLC, Athanor Capital LP, First Trust Advisors LP, Bank of New York Mellon Corp, Barclays PLC, Mackay Shields LLC, and Rafferty Asset Management LLC.
View insider buying and selling activity for TG Therapeutics
.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $19.94.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $2.20 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-172,870,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. TG Therapeutics employs 105 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is www.tgtherapeutics.com.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.